Keytruda was also studied in people with RCC along with another oral medicine called lenvatinib. People in this trial got either Keytruda plus lenvatinib, lenvatinib plus everolimus, or sunitinib.

Keytruda (pembrolizumab) and Eisai’s TKI inhibitor, Lenvima (lenvatinib) in combination with chemotherapy for treating certain types of gastroesophageal adenocarcinoma. The LEAP-015 study ...

A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

MSD’s Keytruda is an anti-PD1 monoclonal antibody ... Eisai and MSD launched their collaboration for the LEAP trials series (LEnvatinib And Pembrolizumab) in 2015. The companies are also ...

Overall, the results with Keytruda are very similar to that seen ... also recently picked up approval for a rival TKI – Lenvima (lenvatinib) – in the US and Europe, and Merck’s vice ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo. The conversion to ...

Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

In metastatic urothelial carcinoma, Padcev plus Keytruda elicited responses in the first-line setting, with Padcev showing benefit in later lines. Among patients with metastatic urothelial carcinoma — ...

FDA approved Keytruda with Herceptin and chemotherapy for HER2-positive gastric/GEJ adenocarcinoma with PD-L1 expression. KEYNOTE-811 study showed improved progression-free and overall survival with ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...